AndroScience Corporation

AndroScience Corporation Awarded A $3.8 Million, 3-Year Milestone-Driven, Cooperative Translational Research Grant from the NIH To Develop An Oral Treatment for Spinal Bulbar Muscular Atrophy (Kennedy’s Disease)

Fri, 31 Dec 2010 06:57:31 PST

SAN DIEGO, CA – January 25, 2011 – AndroScience Corp. (ASC), based in San Diego, California, announced receiving a $3.8 Million, 3-year milestone-driven, cooperative translational research grant from the National Institute of Neurological Disorders and Stroke (NINDS) of the National Institutes of Health (NIH). Through a joint research effort with the Neurogenetics Branch of the NINDS, ASC will use the funding to pursue development of an oral drug treatment for spinal and bulbar muscular atrophy (SBMA) or Kennedy’s Disease, a rare hereditary neurodegenerative disease, which currently has no approved drug available to patients. Key pathological features of SBMA include progressive motor neuropathy and androgen insensitivity syndrome caused by a distinctive mutation within the androgen receptor (AR) gene. ASC has developed a unique platform of therapeutic small molecule drugs, which selectively and potently enhance degradation of the AR protein, termed AR degradation enhancers (ARD enhancers).

AndroScience Corporation forms Strategic Alliance with Taiwan based Orient Europharma to Develop Novel Topical Acne Therapeutic

Wed, 26 May 2010 06:06:19 PST

San Diego, CA May 20, 2010, AndroScience Corporation (ASC) announced today the forming of a strategic partnership with Orient Europharma Co. Ltd. (OEP) of Taiwan. The collaborative agreement centers on the clinical development and commercialization of ASC’s lead therapeutic candidate, ASC- J9^® as a topical anti-acne product. Under terms of the agreement OEP is responsible for clinical study expenses related to an ASC-J9^® phase IIb multi center trial in acne vulgaris. Scheduled to commence in September 2010, the 180 patients, double-blinded, placebo controlled efficacy study will be jointly conducted at clinical sites in Taiwan and the USA.

AndroScience Corporation Announces Phase 2a Study Results on ASC-J9® for the Treatment of Acne

Fri, 06 Mar 2009 10:13:13 PST

San Diego, CA. - March 6, 2009, AndroScience Corporation (ASC^TM), a developmental stage pharmaceutical company announced results of a Phase 2a dose-ranging study of their lead clinical compound for the treatment of acne. The randomized, double-blinded, vehicle-controlled study completed in late 2008 enrolled 186 patients with acne and consisted of twice daily topical applications of ASC-J9^®cream for 12 weeks to evaluate safety and ascertain preliminary efficacy.

September 2007 – Phase 2 Clinical Trial in Acne Vulgaris Begins Enrollment

Sat, 01 Sep 2007 12:27:52 PST

AndroScience Corporation (ASC), a San Diego-based biotech company, is developing ASC-J9^®as a topical agent for the treatment of acne.

June 2007 – Financing and May 2007 - Clinical Trials in Humans with Acne Vulgaris

Sat, 24 Feb 2007 12:30:37 PST

AndroScience has completed a $6.4 million private-equity financing. The company’s latest round of financing was led by President Life Sciences Co., Ltd., joined by Eminent Venture Capital and other private investors.

AndroScience Corporation (ASC), a San Diego based biotech company,
is developing ASC-J9 as a topical agent for the treatment of acne.

Press Release March 2007 and February 2007

Thu, 01 Feb 2007 12:34:28 PST

March 2007 – A potential treatment using AndroScience’s compound, ASC-J9^®, for a neurodegenerative disorder is published in Nature Medicine

February 2007 - AndroScience Corporation begins Clinical Trials in Humans with Acne Vulgaris

AndroScience Corporation Enters Clinical Stage

Fri, 26 Jan 2007 12:38:45 PST

San Diego, January 26, 2007 – AndroScience Corporation, a privately held biotech company, has successfully filed an IND for acne indication and will proceed with Human Clinical Trials in the first quarter of 2007.

Press Release - December 2005, January 2006, March 2006

Fri, 24 Mar 2006 12:44:30 PST

Press Release

December 2006 - Biotech Companies with a Taiwan connection

December 22, 2005 - AndroScience announces it had a successful pre-IND Meeting with the FDA for its lead drug candidate ASC-J9 ™

January 2006 - “Biotech Scene Has Taiwanese Accent”

March 2006 - American Academy of Dermatology (AAD) Poster Award: Dr. Charles Shih, CEO of AndroScience Corp. presented a poster titled “Androgen receptor degradation enhancer:

Press Release - Small Business Innovation Research (SBIR) grant

Fri, 13 Jan 2006 12:42:06 PST

JULY 13, 2006: AndroScience Corporation ("ASC"), a privately held drug discovery company based in San Diego, is pleased to announce the award of $800,000 of a Phase II, Small Business Innovation Research (SBIR) grant

Androgen Receptor Degradation (ARD) Enhancer

Wed, 28 Sep 2005 12:49:38 PST

AndroScience Corporation’s abstract entitled “Androgen Receptor Degradation (ARD) Enhancer: A Potential Application for Topical Treatment of Acne Vulgaris” has been accepted for presentation (selected for Poster Exhibit and Poster Discussion Sessions) at the 64th Annual Meeting of the American Academy of Dermatology to be held on March 3 - 7, 2006 in San Francisco.

AndroScience Corporation Selected to Present at the Fall 2005 RTA / CONNECT Venture Roundtable

Mon, 12 Sep 2005 12:51:56 PST

San Diego, September 12, 2005 – AndroScience Corporation today announced that it has been chosen to present at “RTA / CONNECT Venture Roundtable” on September 22, 2005.

Androgen Receptor Degradation (ARD) Enhancer

Fri, 22 Jul 2005 12:54:44 PST

AndroScience Corporation presented an abstract on the use of its novel Androgen Receptor Degradation (ARD) Enhancer in Acne and Alopecia at the American Academy of Dermatology Association Meeting on July 20-24, 2005 in Chicago.

People to watch: Charles Shih

Fri, 27 May 2005 13:07:07 PST

May 27, 2005
Company: AndroScience Corp.
Title: Chief executive
Age: 61

AndroScience Corporation Selected as a Finalist to Present at 21st Annual CONNECT Financial Forum

Mon, 21 Mar 2005 13:15:04 PST

AndroScience Corporation today announced that it has been chosen to present at “The 21st Annual CONNECT Financial Forum” on April 14th.

Androgen Receptor Degradation (ARD) Enhancer in Acne and Alopecia has been accepted

Mon, 14 Mar 2005 13:13:08 PST

March 14, 2005 – AndroScience Corporation’s abstract on the use of its novel Androgen Receptor Degradation (ARD) Enhancer in Acne and Alopecia has been accepted by the American Academy of Dermatology Association Meeting on July 20-24, 2005 in Chicago.